BioSpace News Archive

Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced that the United States Patent and Trademark Office (USPTO) issued US patent No. 11,517,545 under the title “Treatment of Moderate and Severe Gastroparesis.”

Amarin Corporation plc (NASDAQ:AMRN) today announced that Switzerland’s Swissmedic has granted approval to VAZKEPA (icosapent ethyl). Swissmedic approved VAZKEPA to reduce risk of cardiovascular events in adult statin-treated patients at high cardiovascular risk with elevated triglycerides (≥ 150 mg/dL [≥ 1.7 mmol/L]) and established cardiovascular disease, or diabetes and at least one other cardiovascular risk factor.

Accord Healthcare, Inc., a leading generic pharmaceutical company, has added Bendamustine Lyo. Injection to its line of chemotherapy drugs.

Sarcopenia is a degenerative condition that tends to affect older people, and low muscle mass and strength are the main indicators.

HeartBeam, Inc. (NASDAQ: BEAT)today announced it has signed an agreement (the “Agreement”) with Evolve Manufacturing Technologies (“Evolve”), a contract medical device manufacturing company, to build the credit card-sized AIMIGo 3D vector electrocardiogram (VECG) recording device that provides a 12 lead ECG readout for remote heart attack detection.

Medical device and technology company Lazurite has received recognition from Medical Device Network Excellence Awards & Rankings, one of the largest, most prestigious, and widely recognized programs in the industry.

EPIC BIO announced that Amber Salzman, Ph.D., chief executive officer of Epic Bio, was selected as one of 20 influential women in biopharma by Endpoints News.

Aurion Biotech, whose mission is to restore vision to millions of patients with its life-changing regenerative therapies, today announced it has appointed Dr. Jonathan Sparks as chief legal officer.

Inizio, a strategic partner for companies in health and life sciences, has today announced the acquisition of Evolution Road, a digital innovation company in life science omnichannel, digital marketing and digital health strategy.

Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), is pleased to announce that it has initiated its 7-day dose-ranging, toxicology study, using rats, for its lead molecule MB-204. This is a vital step in preparation to initiate FDA Phase I human clinical trials.